[Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004300
German
Original Title:
Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid (HIV-1-Infektion [Kinder ≥ 2 bis < 6 Jahre und ≥ 14 kg Koerpergewicht])
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-116.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-116_elvitegravir-cobicistat-emtricitabin-tenofoviralafenamid_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- HIV Infections
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Tenofovir
- Cobicistat
- Anti-HIV Agents
- Emtricitabine
- HIV Integrase Inhibitors
Keywords
- Elvitegravir
- Cobicistat
- Emtricitabine
- Tenofovir Alafenamide
- HIV Infections
- Child
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.